Boston Scientific Corporation — Form 8-K
Filed: October 7, 2026; earliest reported event: October 1, 2026. This filing reports executive appointments and compensation arrangements, not quarterly or annual financial results.
Business context and reporting period
Boston Scientific is a Delaware corporation whose common stock (BSX) and 0.625% senior notes due 2027 (BSX27) trade on the New York Stock Exchange. The filing concerns leadership changes effective in 2027.
Financial and compensation information
The filing provides no revenue, profit, cash flow, margins, debt balances, liquidity measures, or other operating results. For Joe Fitzgerald’s COO role, effective January 1, 2027, disclosed compensation includes annual base salary of $1,050,000, an annual bonus target of 110% of base salary, and a 2027 equity award with a stated grant-date fair value of $7,000,000, expected in February 2027. The award is expected to include stock options and restricted stock units, including performance-based RSUs, generally vesting 25% per year. Other disclosed arrangements include deferred-bonus eligibility, retirement-plan benefits, and change-in-control benefits subject to their terms.
Material changes and management commentary
- Joe Fitzgerald, currently Executive Vice President and Group President, Cardiovascular, will become Executive Vice President and Chief Operating Officer on January 1, 2027. He has worked at the company since 1990.
- Emily Woodworth (Collins), currently Global Controller and Chief Accounting Officer, was appointed Senior Vice President, Global Finance Controller and Finance Transformation, effective March 1, 2027. She will cease serving as Chief Accounting Officer on that date. The filing states her transition is not due to disagreement with the company on financial statements, internal controls, operations, policies, or practices.
- Mark Bickel was appointed Senior Vice President, Global Accounting Controller and Chief Accounting Officer, effective March 1, 2027. He currently serves as Senior Vice President, Finance and Global Controller of the Cardiovascular business and is an active CPA. His compensation is described generally, without specific amounts.
Outlook, risks, and unusual items
The filing gives no business or financial guidance and identifies no new financial contingencies. Fitzgerald’s compensation includes retirement benefits and potential change-in-control payments, subject to the applicable plans and agreements. The filing references previously disclosed related-party transactions involving Fitzgerald in the company’s March 18, 2026 proxy statement; it does not restate their details.
Investor facts to verify
- Confirm the effective dates of the COO and Chief Accounting Officer transitions: January 1 and March 1, 2027, respectively.
- Review Fitzgerald’s full offer letter and applicable incentive, retirement, and change-in-control plan documents for terms, vesting, and potential obligations.
- Review the cited 2026 proxy statement for details of Fitzgerald’s related-party transactions.